Madrigal reports real-world data showing Rezdiffra improves liver health measures through 12 months
Bitget2026/10/27 12:09- Madrigal Pharmaceuticals will present new Rezdiffra clinical and real-world data at AASLD’s The Liver Meeting, Nov. 5-9, 2026, in Denver.
- Real-world findings show improvements in liver health through 12 months among patients receiving the MASH treatment in routine clinical practice.
- The RESONANCE program will contribute 13 abstracts; the largest real-world dataset covers more than 12,000 patients.
- Clinical abstracts further characterize Rezdiffra’s positive effects on treatment-response measures, cardiovascular risk markers and patient-reported outcomes.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Crypto prices
More
